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Abstract
Background: Overexpression of the human c-MYC (MYC) oncogene is one of the most frequently implicated events in the
pathogenesis of hepatocellular carcinoma (HCC). Previously, we have shown in a conditional transgenic mouse model that
MYC overexpression is restrained from inducing mitotic cellular division and tumorigenesis in the adult liver; whereas, in
marked contrast, MYC induces robust proliferation associated with the very rapid onset of tumorigenesis in embryonic and
neonatal mice.
Methodology/Principal Findings: Here, we show that non-genotoxic hepatotoxins induce changes in the liver cellular
context associated with increased cellular proliferation and enhanced tumorigenesis. Both 5-diethoxycarbonyl-1,4-
dihydrocollidine (DDC) and carbon tetrachloride (CCl4) cooperate with MYC to greatly accelerate the onset of liver cancer in
an adult host to less than 7 days versus a mean latency of onset of over 35 weeks for MYC alone. These hepatotoxin-
enhanced liver tumors grossly and histologically resemble embryonic and neonatal liver tumors. Importantly, we found that
MYC overexpression is only capable of inducing expression of the mitotic Cyclin B1 in embryonic/neonatal hosts or adult
hosts that were treated with either carcinogen.
Conclusion/Significance: Our results suggest a model whereby oncogenes can remain latently activated, but exposure of
the adult liver to hepatotoxins that promote hepatocyte proliferation can rapidly uncover their malignant potential.
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Introduction
MYC is a proto-oncogene that regulates normal cellular growth,
proliferation, apoptosis, and differentiation [1]. MYC is frequently
overexpressed or mutated in human cancers and is thought to
contribute to tumorigenesis by inducing autonomous cellular
growth and proliferation, blocking differentiation, and inducing
genomic instability [1–5]. Aberrant MYC oncogene expression
has been frequently observed in primary human and rodent liver
tumors [6–8]. Importantly, MYC expression is sufficient to induce
tumor formation in murine models, with liver-specific overexpres-
sion directed by the albumin enhancer/promoter or the alpha-1-
antitrypsin promoter resulting in HCC [9,10]. However, the
tumor incidence in these mice is relatively low and the latency is
long. Notably, when MYC is co-expressed in the murine liver with
either Transforming growth factor alpha (TGF-alpha) or E2F
transcription factor 1 (E2F1), the onset of tumorigenesis is
significantly accelerated [11–13]. These data suggest that MYC
activation can be significantly augmented by various complemen-
tary stimuli, providing a system by which modifiers of the tumor
phenotype may be revealed.
Epidemiological studies in humans, as well as data from animal
models, support the idea that the liver is more susceptible to
neoplastic transformation during states of liver growth and
regeneration [14,15]. Patients with alcohol-induced cirrhosis of
the liver were found to be at greater risk of developing
hepatocellular carcinoma than those without cirrhosis [16].
Similarly, various hepatotoxins have been reported to enhance
liver tumorigenesis in many contexts, including mice that are
transgenic for hepatitis b virus (HBV) protein or TGF-alpha
overexpression [17–19]. Together, these data support the model of
accelerated liver tumorigenesis as a result of changes in the liver.
Notably, different hepatotoxins damage distinct regions of the liver
lobule and have been shown to elicit different cells in the hepatic
lineage to restore hepatocyte loss during tissue regeneration,
thereby influencing the cellular origin of HCC (Figure 1A) [20,21].
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2493Based on the differential effect of various toxins, some chemical
carcinogenesis models have favored the hepatocyte as the
precursor to HCC, while others have implicated liver progenitor
cells (oval cells) as the cell of origin for HCC [22–24].
Recently, we have described the use of the tetracycline-
regulated (Tet) system to develop a conditional transgenic model
of MYC-induced HCC [25,26]. Using this system, we found that
MYC’s ability to induce mitotic division and tumorigenesis in the
liver is developmentally regulated [26]. In the permissive context
of an embryonic or neonatal liver, in which hepatocytes are
actively undergoing mitotic cellular division, MYC overexpression
further increased cellular proliferation and resulted in the almost
immediate onset of liver tumorigenesis. In contrast, when
overexpressed in mitotically quiescent adult murine hepatocytes,
MYC was capable of inducing cellular growth and DNA
replication, but was prohibited from inducing mitotic division
and resulted in HCC only after a prolonged latency. Hence, the
cellular and developmental context of the host appears to play a
critical role in defining the ability of MYC to induce tumorigenesis
in the liver.
Non-genotoxic hepatotoxins are examples of agents that could
be responsible for changes in the liver that would enhance the
ability of oncogenes such as MYC to induce liver tumorigenesis.
CCl4 is a well characterized carcinogen that causes centrilobular
destruction of hepatocytes and triggers mature hepatocytes to
proliferate and reconstitute the lost liver mass (Figure 1A) [27,28].
Other agents such as DDC have also been reported to cause liver
damage associated with the proliferation of oval cells in the
periportal area of the hepatic lobule, however, as of yet have not
been reported to be carcinogens (Figure 1A) [29–31]. Here we
show that both DDC and CCl4 similarly facilitate MYC-induced
initiation of hepatocyte proliferation and tumorigenesis in the
adult liver. Our findings suggest a model whereby external stimuli
may unveil latent oncogene activation in the mature liver.
Results
DDC and CCl4 treatment accelerate MYC-induced HCC in
adult hosts
To examine the effects of DDC on MYC’s ability to induce
tumorigenesis in the adult liver, 6-week-old adult mice were fed a
diet containing 0.1% DDC [29]. MYC was induced in one cohort
of mice (MYC ON/DDC) and kept inactive in controls (MYC
OFF/DDC) (Figure 1B). To distinguish between DDC-specific
and other hepatotoxin effects, a separate cohort of transgenic mice
were injected with CCl4 twice weekly for the duration of the
experiment (4 months), either in the presence (MYC ON/CCl4) or
absence (MYC OFF/CCl4) of MYC overexpression (Figure 1B).
As an additional control, adult mice in which MYC was
overexpressed by itself (MYC ON) or kept inactive (MYC OFF)
were also monitored (Figure 1B). Remarkably, mice that
overexpressed MYC in conjunction with either DDC or CCl4
treatment (MYC ON/DDC and MYC ON/CCl4) developed liver
cancers at a substantially accelerated onset as compared to the
control MYC ON mice (Figure 2). Specifically, the rate at which
all MYC ON/DDC and MYC ON/CCl4 animals were moribund
with tumor burden was 31 and 40 days, respectively, compared to
183 days for MYC ON by itself. Indeed, by the time hepatotoxin-
associated mortality was at 100%, the MYC ON cohort had yet to
demonstrate morbidity. Interestingly, the rapid onset of liver
tumorigenesis in MYC ON/DDC and MYC ON/CCl4 mice was
Figure 1. Examining the Impact of DDC and CCl4 Damage on
MYC-Induced HCC. (A) Schematic of the liver lobule illustrating that
DDC causes liver damage associated with the emergence and
proliferation of oval cells in the periportal area of the hepatic lobule,
while CCl4 causes damage associated with the destruction of
hepatocytes near the central vein and triggers mature hepatocytes to
proliferate. (B) Schematic of experimental design. Eight different
cohorts of mice were monitored for tumorigenesis. MYC was activated
(MYC ON) or kept inactive (MYC OFF) in mice: at birth, in 6–10 week old
adult, in 6–10 w old adult mice treated with DDC, or in 6–10 w old adult
mice treated with CCl4. Mice were sacrificed when moribund with
tumor burden.
doi:10.1371/journal.pone.0002493.g001
Figure 2. DDC and CCl4 Cooperate with MYC to Induce
Accelerated Liver Tumorigenesis. Shown are Kaplan-Meier survival
curves for 6–8 w adult mice that overexpressed MYC and were
simultaneously treated with: nothing (filled black square), DDC (filled
blue circle), or CCl4 (filled blue diamond). Adult mice treated with
hepatotoxins in the absence of MYC overexpression (MYC OFF) are
displayed with the corresponding open shape: nothing (empty black
square), with DDC (empty blue circle), or CCl4 (empty blue diamond).
Also shown are survival curves of neonatal mice in which MYC was
either overexpressed (filled red triangle), or remained inactive (empty
red triangle) starting at birth. Cohorts consisted of 5–10 mice. MYC
transgene expression was activated by removal of doxycycline from the
mouse drinking water on the day of hepatotoxin treatment initiation.
Mice were sacrificed when moribund with tumor burden.
doi:10.1371/journal.pone.0002493.g002
Hepatotoxin/MYC-Induced HCC
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livers (Figure 2). Mice in which MYC was inactive (MYC OFF/
DDC, MYC OFF/CCl4 and MYC OFF) remained tumor free for
the duration of the experiment as expected (4 months, Figure 2).
DDC and CCl4 cooperate with MYC to induce diffuse HCC
Since tumor latency was dramatically reduced upon hepato-
toxin treatment, it was necessary to investigate whether the
resulting disease appeared phenotypically similar. Upon gross
examination, MYC ON/DDC and MYC ON/CCl4 mice
developed tumors associated with three-fold enlarged livers with
a multitude of coalescing tumor nodules (Figure 3F, H). As
observed with tumor latency, hepatotoxin-accelerated HCC
appeared similar to the MYC-induced neonatal livers, demon-
strating a diffuse tumor phenotype (Figure 3D) [26]. In contrast,
adult mice that overexpressed MYC by itself developed enlarged
livers with multiple discrete tumor nodules, as previously described
(Figure 3B) [26]. Although MYC OFF/DDC mice did not develop
tumors, they exhibited progressive abdominal enlargement during
the duration of DDC feeding, reaching a peak at about 4 weeks.
Grossly, this abdominal growth was associated with 2-fold
enlarged livers (Figure 3A, E). In contrast, MYC OFF/CCl4
livers were either equal to or 20% smaller than a normal liver and
associated with a nodular appearance (Figure 3A, G).
MYC expression does not enhance hepatotoxin-induced
oval cell expansion
To further characterize the effects of DDC and CCl4 on MYC-
induced HCC formation in adult liver, histological analysis was
performed. In MYC OFF/DDC livers, we found evidence for liver
injury associated with the expansion of oval cells near the
periportal areas (Figure 4D). This oval cell expansion reached a
peak three-to-four weeks after DDC diet initiation, consistent with
previous findings [29], and may have contributed to the marked
liver growth. MYC OFF/CCl4 mice developed liver injury
associated with post-necrotic lobular collapse (Figure 4G). This
hepatocyte death and necrosis may explain the decrease in size of
MYC OFF/CCl4 livers relative to normal livers (Figure 3A, G).
In addition, MYC ON/DDC and MYC ON/CCl4 livers
exhibited evidence for microcarcinomas as early as ten days after
MYC activation (Figure 4E, H), prior to developing diffuse HCC
(Figure 4F, I). Eighty-six percent of microcarcinomas found in
MYC ON/DDC, and 50% of those found in MYC ON/CCl4
livers were located adjacent to periportal areas of the liver lobule
(Figure 4E, H). MYC ON adult mice also developed 93% of
microcarcinomas near the periportal areas, although after a much
longer latency period (Figure 4B). These results are consistent with
the previously suggested notion that many HCC’s derive from the
malignant expansion of less mature hepatocytes or oval cells [23].
In order to address whether the reduced tumor latency observed
in DDC-treated mice may have been due to an increase in the oval
cell population, immunohistochemistry (IHC) was employed.
Accordingly, an antibody specific for the A6 antigen, known to
be expressed on oval cells, was utilized [32]. Prior to induction, few
cells were reactive for the A6 antigen, as expected (Figure 5A).
Upon initiation of DDC treatment, oval cells emerged in the
periportal areas by 7 days (Figure 5C) and continued to expand,
reaching a peak between 3 and 4 weeks (Figure 5E, G). It was
expected that, if oval cell expansion was critical for increased
Figure 3. DDC and CCl4 Cooperate with MYC to Induce Diffuse
HCC. (A) A normal adult liver (MYC OFF Adult). (B) An adult liver tumor
(MYC ON Adult). (C) A normal 4 w old liver (MYC OFF Neonate). (D) A
neonatal liver tumor (MYC ON Neonate). (E) An adult liver 3–4 weeks
after continuous DDC treatment (MYC OFF/DDC). (F) An adult liver
tumor induced by MYC overexpression in conjunction with continuous
DDC treatment (MYC ON/DDC). (G) An adult liver 4 weeks after
continuous CCl4 treatment (MYC OFF/CCl4). (H) An adult liver tumor
induced by MYC overexpression in conjunction with continuous CCl4
treatment (MYC ON/CCl4). Representative animals from each cohort are
presented. Note that toxin-accelerated HCC are diffuse, similar in
appearance to neonatal tumors. In contrast, normal MYC-induced adult
tumors present as a distinct, multifocal disease.
doi:10.1371/journal.pone.0002493.g003
Figure 4. Hepatotoxins Induce Liver Toxicity and Cooperate
with MYC to Induce Diffuse HCC’s Arising from Periportal
Areas. (A) Histology of a normal adult liver. (B) Histology of a MYC-
induced microcarcinoma that developed in a periportal area of the liver.
Inner panel is a magnified view of the microcarcinoma. (C) Histology of
a MYC-induced, multifocal adult liver tumor. (D) Histology of an adult
liver 3 w after continuous DDC treatment. The liver lobule exhibits oval
cell expansion radiating from the periportal area, typical of DDC-
induced injury. (E) Histology of a MYC and DDC-induced microcarci-
noma that stems from the periportal area. Inner panel is a magnified
view of the microcarcinoma. (F) Histology of a MYC and DDC-induced
diffuse liver tumor. (G) Histology of an adult liver after 4 weeks of
continuous CCl4 treatment. Microvesicular lipidosis can be seen in the
centrilobular area of the liver lobule. (H) Histology of a MYC and CCl4-
induced microcarcinoma that stems from the periportal area. Inner
panel is a magnified view of the microcarcinoma. (I) Histology of a MYC
and CCl4-induced diffuse liver tumor. Representative data is shown.
doi:10.1371/journal.pone.0002493.g004
Hepatotoxin/MYC-Induced HCC
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DDC treatment would result in a significant increase in these cells.
However, the increase observed in oval cells was comparable
between MYC ON and MYC OFF conditions at all time points
(Figure 5A–H), suggesting that MYC overexpression may not
contribute to further oval cell expansion in the liver. Furthermore,
no A6 positive cells were detected in MYC ON/DDC-induced
neoplastic foci (Figure 5H) or in pre-neoplastic livers in which MYC
was expressed for 30 days (Figure 5B). One possible explanation for
these data is that some oval cells were undergoing neoplastic
transformation, or, alternatively, differentiating into immature
hepatocytes and thus were no longer expressing the A6 antigen.
DDC and CCl4 facilitate MYC-induced mitotic cellular
division and proliferation in the adult liver.
In the adult murine liver, the ability of MYC to initiate
tumorigenesis is associated with the ability to induce the cellular
growth and DNA replication but not mitotic division of
hepatocytes [26]. It has been demonstrated that continuous
exposure to hepatotoxins such as DDC and CCl4 causes liver
injury that is accompanied by tissue regeneration. We speculated
that DDC and CCl4 were contributing to accelerated MYC-
induced HCC by altering the liver context, thereby enhancing the
mitotic division of hepatocytes. As such, liver cell proliferation was
measured by Ki67 immunofluorescence and IHC for phosphor-
ylated Histone H3 (Figure 6A–C). DDC and CCl4 treatments both
resulted in a significant increase in the proliferative index,
regardless of MYC expression. Indeed, either DDC or CCl4
treatment for 17 days alone was sufficient to increase cellular
proliferation and mitosis above that resulting from MYC
overexpression for the same duration. However, this effect was
exaggerated when combined with oncogene activation. As
measured by Ki67, MYC ON/DDC and MYC ON/CCl4 livers
exhibited a 30 and 40 percent increase in hepatocyte proliferation,
respectively, as compared to DDC and CCl4-treated MYC OFF
livers (Figure 6A). In addition, a 300 and 250 percent increase in
hepatocyte mitotic division as measured by phospho-Histone H3
was observed in cohorts with MYC on and exposure to either
DDC or CCl4 (Figure 6C). Notably, the proliferation observed in
MYC ON/DDC samples was diffuse, and not localized to the
periportal areas of the liver lobule, further suggesting that these
HCC’s may not originate from the oval cells (Figure 6 and data
not shown). Importantly, MYC induction alone had only a modest
impact on hepatocyte proliferation within 17 days (Figure 6A–C).
Thus, hepatotoxins can similarly promote continuous and diffuse
hepatocyte proliferation irrespective of the targeted region of the
liver lobule.
We previously reported that MYC is restrained from inducing
the mitotic division of adult hepatocytes, and consequently for
HCC formation, due to a p53-dependent cell cycle arrest [26]. To
determine if loss of p53 is similarly necessary for MYC to induce
HCC in the context of CCl4 or DDC, we examined p53 protein
expression by Western analysis (Figure 6D). In contrast to our
previous results, we found that adult tumor onset in MYC ON/
CCl4 and MYC ON/DDC mice was not associated with a loss of
p53 protein expression (Figure 6D). Thus, it appears that
treatment with hepatotoxins allows for evasion of p53-cell cycle
arrest upon induction of MYC overexpression, thereby allowing
MYC to induce increased mitotic division and HCC. Interestingly,
this is in agreement with our results demonstrating that p53 loss is
not required for tumorigenicity in the neonatal liver [26].
DDC and CCl4 treatment permit MYC-induced Cyclin B1
expression
MYC is thought to promote unrestrained proliferation and
tumorigenesis in part by directly inducing the transcription of
genes involved in cell cycle progression and mitosis [1,33–35].
However, while MYC can rapidly induce mitotic entry in neonatal
livers, oncogene activation initially results in hepatocyte hypertro-
phy in adult livers and only results in mitosis in this context upon
neoplasia [26].
To determine if the accelerated tumorigenesis in hepatotoxin-
treated adult livers is due to differences in MYC’s ability to induce
the expression of genes involved in mitotic division, we measured
the expression of known transcriptional targets of MYC by
Quantitative Real-Time PCR (qRT-PCR). As a control, MYC
expression was shown to increase in a temporal manner in all
samples, with no significant difference observed in hepatotoxin-
treated livers (Figure 7A). Similarly, no differences were observed
in ODC and Nucleolin mRNA expression levels, two canonical
targets of MYC’s transcriptional activity (Figure 7B, C). However,
when Cyclin B1 expression was examined, we discovered that
MYC ON/DDC and MYC ON/CCl4 livers exhibited a 250 and
150 percent increase in Cyclin B1 mRNA, respectively, compared
Figure 5. MYC Overexpression Does Not Contribute to Oval Cell Expansion. A6 Immunohistochemistry of: (A) a normal adult liver, (B) an
adult liver in which MYC has been activated for 30 days, (C) an adult liver treated with DDC for 7 days, (D) an adult liver that overexpressed MYC in
conjunction with DDC treatment for 7 days, (E) an adult liver treated with DDC for 17 days, (F) an adult liver that overexpressed MYC in conjunction
with DDC treatment for 17 days, (G) an adult liver treated with DDC for 28 days, and (H) an adult liver with adjacent tumor foci that stemmed from
MYC and DDC treatment for 28 days. A6 positive cells are evident in the periportal areas but not in the tumors. Representative data is shown.
doi:10.1371/journal.pone.0002493.g005
Hepatotoxin/MYC-Induced HCC
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Cyclin B1 mRNA was also elevated in MYC OFF/DDC and
MYC OFF/CCl4 livers relative to MYC ON and normal adult
livers (Figure 7D). Interestingly, the pattern of Cyclin B1
expression in MYC ON/DDC and MYC ON/CCl4 is strikingly
similar to the expression pattern in neonatal livers in which MYC
expression was induced.
Our results suggest that when MYC is overexpressed in
conjunction with DDC or CCl4 treatment, it may be more
capable of transactivating genes involved in mitotic regulation in
the adult liver. Moreover, the difference in Cyclin B1 expression
could, in part, be responsible for the dramatic difference in MYC’s
ability to induce the mitotic division of hepatocytes in the context
of DDC or CCl4.
Discussion
Here, we show that two non-genotoxic hepatotoxins, DDC and
CCl4, can cooperate with MYC to induce robust mitotic cellular
division and the near immediate onset of liver tumorigenesis. Our
results have implications for the mechanisms by which oncogenes
such as MYC induce and are restrained from causing HCC.
Previously, we have shown that MYC overexpression induces
robust cellular proliferation in embryonic and neonatal hepato-
cytes, but, in marked contrast, induced cellular growth and DNA
replication without mitotic cellular division in the adult liver [26].
We speculated that for MYC to induce liver cancer in adult hosts,
the liver context must be changed, presumably through factors
that stimulate hepatocyte proliferation. Indeed, both DDC and
CCl4, toxins that target distinct regions of the liver [28–30] were
found to markedly increase the ability of MYC to induce mitotic
cellular division and permit the almost immediate onset of HCC.
Our results suggest that oncogenes such as MYC can become
latently active in the liver but only upon subsequent exposure to a
hepatotoxin is their malignant potential manifested.
Our data are consistent with the general notion that the liver is
most permissive to malignant transformation under circumstances
when hepatocytes are undergoing cellular proliferation [26,36].
Moreover, our observations further validate previous reports that
MYC can cooperate with agents that modulate the liver and
thereby stimulate hepatocyte proliferation. Most notably, MYC
has been shown to cooperate with TGF-alpha and phenobarbital
to induce accelerated tumorigenesis in the adult murine liver [37].
Our model recapitulates the latency of tumor formation associated
Figure 6. Hepatotoxins Facilitate MYC-Induced Proliferation Irrespective of p53 Status. (A) Immunofluorescence for Ki67 expression as a
marker of liver cell proliferation is presented. (B) Bar graphs illustrating a ratio of Ki67 positive hepatocytes to total hepatocytes as a relative measure
of hepatocyte proliferation are shown. (C) Bar graphs illustrate a ratio of phospho-Histone-H3 positive hepatocytes to total hepatocytes as a relative
measure of hepatocyte mitotic division. Gray bar graphs represent normal adult livers in which MYC was either overexpressed (MYC ON/Adult), or
kept inactive (MYC OFF/Adult). Red bar graphs represent DDC-treated livers in which MYC was either overexpressed (MYC ON/DDC), or kept inactive
(MYC OFF/DDC). Blue bar graphs represent CCl4-treated livers in which MYC was either overexpressed (MYC ON/ CCl4), or kept inactive (MYC OFF/
CCl4). T represents a liver tumor. Results are based on an average of 4 samples per time-point. Statistical significance was measured using a Mann
Whitney test: graph in (A) (* P,0.05, ** P,0.05), and graph in (B) (* P,0.05). (D) Western blot analysis for p53 protein expression after different
durations of MYC overexpression in: Normal, DDC-treated, and CCl4-treated livers. As a positive control, a lymphoma cell line that overexpressed a
mutant p53 was used. Normal FVB/N adult liver was used as a negative control.
doi:10.1371/journal.pone.0002493.g006
Hepatotoxin/MYC-Induced HCC
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that either enhance or repress tumorigenesis. To our knowledge,
our report is the first to describe that hepatotoxins cooperate with
MYC overexpression to induce accelerated HCC specifically in
the context of an adult murine liver.
A possible explanation for our findings is that MYC appears to
be only capable of inducing the activation of Cyclin B1-Cyclin-
dependent kinase 1 (Cdk1) in embryonic/neonatal hepatocytes or
in adult livers treated with hepatotoxins. Elevated Cyclin B1 levels
often precede the onset of tumor cell immortalization and
aneuploidy [38,39]. When we compared Cyclin B1 expression
levels in the different cohorts of mice, we found that treatment
with DDC or CCl4 was associated with elevated Cyclin B1
expression relative to a normal or MYC ON liver. Furthermore,
Figure 7. MYC-induced Proliferation and Tumorigenesis in Hepatotoxin-Treated Livers is Associated with Increased Cyclin B1
Expression. Real-time quantitative PCR of: (A) human c-MYC mRNA, (B) mouse Ornithine Decarboxylase (ODC) mRNA, (C) mouse Nucleolin mRNA,
and (D) mouse Cyclin B1 mRNA. Statistical significance was measured using a Mann Whitney test (* P,0.05, ** P,0.05, *** P,0.05). Gray bar graphs
represent normal adult livers in which MYC was overexpressed for the times indicated. White bar graphs represent normal neonatal livers in which
MYC was overexpressed. Red bar graphs represent DDC-treated livers in which MYC was either overexpressed (MYC ON/DDC) or kept inactive (MYC
OFF/DDC). Blue bar graphs represent CCl4-treated livers in which MYC was either overexpressed (MYC ON/ CCl4) or kept inactive (MYC OFF/ CCl4).
mRNA was quantitated from four different liver samples per time-point.
doi:10.1371/journal.pone.0002493.g007
Hepatotoxin/MYC-Induced HCC
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CCl4 we unveiled evidence for a further increase in Cyclin B1
expression levels. Notably, Cyclin B1 has been shown to be a
direct transcriptional target of MYC [35,41]. Hence, one likely
explanation for these differences is that the Cyclin B1 promoter
region may be more accessible to MYC in hepatotoxin-treated
livers, possibly by regulation of chromatin structure [40].
Alternatively, the increased expression of Cyclin B1 could be
attributed to mitotic signals from the regenerative response
initiated in the liver by CCl4 or DDC damage. Future experiments
will be directed at determining if MYC is directly activating the
transcription of Cyclin B1 in hepatotoxin-treated livers.
Previously, we were able to show that a loss of p53 is associated
with MYC-induced tumorigenesis in the normal adult liver [26].
In contrast, there was no evidence for p53 protein loss in MYC
ON/DDC and MYC ON/CCl4 liver tumors, consistent with our
observations in embryonic or neonatal MYC-induced tumors.
Interestingly, Yin and colleagues recently showed that loss of p53
function cooperates with MYC to induce increased Cyclin B1
expression [41]. Our earlier report supports this mechanism in
that loss of p53 in MYC-induced adult tumors was associated with
elevated Cyclin B1 mRNA. Interestingly, we did not observe a
correlation between p53 protein status and Cyclin B1 expression
in hepatotoxin-treated livers. One possible explanation for this
discordance is that, after exposure of the liver to DDC or CCl4, the
already elevated levels of Cyclin B1 enable MYC to bypass the p53
checkpoint and further drive hepatocyte proliferation.
We hypothesized that one possible mechanism by which DDC
facilitates MYC-induced HCC is by inducing oval cell expansion.
Since these cells more closely resemble embryonic hepatoblasts, we
posited that they may be more susceptible to MYC-induced
tumorigenesis [42,43]. However, when assayed by A6 immuno-
histochemistry, there was no evidence for a difference in oval cell
number between MYC OFF/DDC and MYC ON/DDC livers.
One possible explanation for a lack of change in oval cell number
between MYC ON/DDC and MYC OFF/DDC livers is that
some oval cells were undergoing neoplastic transformation,
thereby losing their oval cell properties and were no longer
expressing the A6 antigen. This idea is further supported by the
fact that the first appearance of neoplastic foci and microcarci-
nomas in the MYC ON/DDC livers occurs as early as 10 days
after MYC activation, and is predominantly located in the
periportal area of the liver. Alternatively, these oval cells could
have also lost their oval cell properties by quickly differentiating to
immature hepatocytes. Our model should be useful in further
investigating the role of oval cells in MYC-induced tumorigenesis.
In contrast to DDC, continuous exposure to CCl4 damages the
liver by causing massive centrilobular necrosis and stimulating an
inflammatory response through the activation of kupffer cells.
Activated kupffer cells produce pro-inflammatory cytokines, such
as Tumor necrosis factor-alpha (TNF-alpha), that can exacerbate
chemical-induced liver injury as well as functioning as hepatic
mitogens [44,45]. TNF-alpha is commonly induced almost
immediately after CCl4 exposure and is responsible for the
activation of nuclear transcription factors that promote the
expression of genes involved in cell cycle progression and mitotic
division [44,46]. It will be interesting to subsequently investigate
the role of CCl4-induced TNF-alpha signaling in MYC-induced
liver tumorigenesis.
In this report, we demonstrate that toxin-mediated liver damage
is sufficient to accelerate MYC-induced HCC formation in adults.
Interestingly, this effect is irrespective of the target of the
hepatotoxin or whether it functions independently as a carcinogen.
Our results are consistent with a model whereby oncogenic events,
such as MYC overexpression, may be generally silent in adult
somatic hepatocytes unless the host is exposed to a liver toxin that
promotes a permissive environment for tumorigenesis.
Materials and Methods
Transgenic mice
The TRE-MYC transgenic line generated for these experiments
was described previously [2]. The LAP-tTA transgenic line was
kindly provided by H. Bujard [47]. MYC expression was activated
by removing doxycycline treatment (100 mg/ml) from the drinking
water of mice transgenic for both TRE-MYC and LAP-tTA.
Tumorigenicity assays
MYC was activated in the liver by removing doxycycline
treatment from the water. For toxin treatment, 6-week-old mice
were either continuously fed a diet containing 0.1% DDC (Sigma-
Aldrich, St. Louis, Missouri, United States) or injected intraper-
itoneally with carbon tetrachloride (Sigma-Aldrich) two times a
week every week until sacrifice. CCl4 was diluted in mineral oil
(Sigma-Aldrich) and administered at a dose of 1 mL per gram of
mouse. Mice were monitored daily and were sacrificed when
moribund with tumor burden. During necropsy, liver tissues were
saved by snap freezing in liquid nitrogen or were prepared for
histology by fixing in 10% buffered formalin for 24 h and then
transferring to 70% ethanol until paraffin embedding. All
procedures were approved by the Animal Care Committee at
Stanford University.
Immunohistochemistry
Tissue sections 4 mm thick were cut from paraffin-embedded
blocks and placed on glass slides. Hematoxylin and eosin (H&E)
staining was performed using standard procedures. The Stanford
Histology Core laboratory prepared paraffin sections and
performed H&E staining. A6 IHC was performed on liver tissue
frozen in O.C.T. (280uC), sectioned at 7 mm, and fixed in 100%
acetone at 220uC for 10 minutes. Phospho-Histone H3 IHC was
performed on formalin-fixed paraffin embedded tissue. Endoge-
nous peroxidase activity was blocked in 0.3% H2O2 in methanol
for 30 minutes, followed by blocking in rabbit or goat serum for
1 hour. The A6 rat monoclonal antibody was applied at a 1:20
dilution for 1.5 hours at room temperature. The A6 antibody was
a generous gift from Dr. Valentina Factor (National Cancer
Institute, National Institutes of Health, Bethesda, Maryland,
United States). The phospho-Histone H3 antibody (#9701, Cell
Signaling Technology, Danvers, Massachusetts, United States) was
applied at a 1:100 dilution overnight at 4uC. Primary antibody
incubation was followed by detection using either the rabbit anti-
rat ABC Elite Kit or the goat anti-rabbit ABC Elite Kit (Vector
Laboratories, Burlingame, California, United States) according to
the manufacturer’s protocol. Color was obtained using diamino-
benzadine/nickel chloride (Vector Laboratories).
Ki67 Immunofluorescence
Ki67 expression was examined by immunofluorescence using a
mouse anti-human Ki67 monoclonal antibody (BD Biosciences,
Palo Alto, California, United States) and the Vector M.O.M. Basic
Kit (Vector Laboratories). Slides were deparaffinized in xylene and
rehydrated in a graded series of ethanols, followed by antigen
retrieval in a microwave for 14 min in antigen unmasking solution
(Vector Laboratories, H-3300). Slides were then incubated in
100 mM glycine twice for 8 min to reduce fluorescent back-
ground. Slides were incubated in avidin for 10 min followed by
biotin for 10 min using the Dako biotin blocking system
Hepatotoxin/MYC-Induced HCC
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States) and subsequently incubated for 1 h in M.O.M. IgG-
blocking reagent diluted 1:4 in PBS. Slides were then incubated for
1 h in mouse anti-human Ki67 monoclonal antibody diluted 1:100
in M.O.M. diluent. Slides were washed in TBST for 3 times for
5 min to reduce background and were then treated with M.O.M.
biotin-labeled anti-mouse IgG, diluted 1:250 in M.O.M. diluent.
Following another 365 min of TBST washes, slides were
incubated for exactly 45 min in Cy3-conjugated streptavidin
diluted 1:800 in PBS (Amersham Biosciences, Piscataway, New
Jersey, United States) in the dark. To visualize nuclei, slides were
counterstained with 0.2 mg/ml DAPI. Ki67-positive cells were
visualized by fluorescence microscopy.
RNA Isolation and cDNA Preparation
Total cellular RNA was isolated from snap-frozen liver tissue
using the RNeasy Kit (Qiagen, Valencia, California, United
States) following the manufacturer’s protocol. The amount of total
RNA was quantified using spectrophotometric OD260 measure-
ments. RNA was reverse transcribed using Oligo(dT)12–18 primers
(Invitrogen, Carlsbad, California, United States) and SuperScript
II Reverse Transcriptase (Invitrogen).
Quantitative Real-Time PCR
qRT-PCR was performed on the ABI Prism 7700 Sequence
Detection System (Applied Biosystems, Foster City, California,
United States) using the SYBR Green PCR Master Mix (Applied
Biosystems). PCR reactions were performed in triplicate in a final
volume of 12 mL. The primer sequences were as follows: MYC
forward 59-ACCAGATCCCGGAGTTGGAA-39, MYC reverse
59-CGTCGTTTCCGCAACAAGTC-39, ODC forward 59-
CTGTGCTTCTGCTAGGATCAATGT-39, ODC reverse 59-
GCCTTAACACAAGCTAAACTTGCA-39, Nucleolin forward
59-GGAGGCCATGGAAGATGGAG-39, Nucleolin reverse 59-
CACCTCTGCCTCCGAAACCT-39, Cyclin B1 forward 59-
ACTTCCTCCGTAGAGCATC-39, Cyclin B1 reverse 59-GCA-
GAGTTGGTGTCCATTC-39, Ubiquitin forward 59-AGCC-
CAGTGTTACCACCAAG-39, Ubiquitin reverse 59-ACCCAA-
GAACAAGCACAAGG-39. Thermal cycling conditions consisted
of the following steps: 95uC for 10 minutes, followed by 40 cycles
of 95uC for 15 seconds, 57uC for 30 seconds, 72uC for 30 seconds,
and a dissociation stage consisting of 95uC for 15 seconds, 60uC
for 15 seconds, and 95uC for 15 seconds. MYC, ODC, Nucleolin,
and Cyclin B1 mRNA expression levels were normalized to
Ubiquitin expression levels and expressed relative to mRNA levels
in a normal liver.
Western Blot. Western analysis was performed using
conventional techniques. Liver tissues were disrupted and
protein was isolated using a tissue homogenizer in NP-40 lysis
buffer. Proteins were electrophoresed on 7.5% Tris-HCl
polyacrylamide gels and transferred onto PVDF membranes.
The membrane was blocked in 5% nonfat dry milk solution in
TBST at 4uC overnight. p53 protein expression was detected using
the NCL-p53-CM5p rabbit polyclonal antibody (Novacastra,
VisionBiosystems, Inc., Norwell, Massachusetts, United States) at
a 1:500 dilution. As a positive control, we used liver tissue from
mice injected with a p53 expressing vector.
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